First Eagle Investment Management LLC Decreases Stake in Artivion, Inc. (NYSE:AORT)

First Eagle Investment Management LLC cut its position in shares of Artivion, Inc. (NYSE:AORT - Free Report) by 4.8% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 591,715 shares of the company's stock after selling 30,133 shares during the period. First Eagle Investment Management LLC owned 1.41% of Artivion worth $16,917,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently added to or reduced their stakes in AORT. RiverPark Advisors LLC lifted its holdings in Artivion by 151.6% during the third quarter. RiverPark Advisors LLC now owns 5,387 shares of the company's stock valued at $143,000 after purchasing an additional 3,246 shares in the last quarter. Quest Partners LLC lifted its stake in shares of Artivion by 2,481,700.0% in the third quarter. Quest Partners LLC now owns 24,818 shares of the company's stock worth $661,000 after buying an additional 24,817 shares in the last quarter. Intech Investment Management LLC lifted its stake in shares of Artivion by 6.6% in the third quarter. Intech Investment Management LLC now owns 10,530 shares of the company's stock worth $280,000 after buying an additional 653 shares in the last quarter. The Manufacturers Life Insurance Company lifted its stake in shares of Artivion by 28.1% in the third quarter. The Manufacturers Life Insurance Company now owns 19,596 shares of the company's stock worth $522,000 after buying an additional 4,295 shares in the last quarter. Finally, FMR LLC lifted its stake in shares of Artivion by 28.0% in the third quarter. FMR LLC now owns 115,184 shares of the company's stock worth $3,066,000 after buying an additional 25,176 shares in the last quarter. 86.37% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Artivion Trading Up 0.3 %

Artivion stock traded up $0.08 during midday trading on Tuesday, hitting $24.16. 359,774 shares of the stock were exchanged, compared to its average volume of 260,508. Artivion, Inc. has a fifty-two week low of $19.36 and a fifty-two week high of $32.33. The stock has a market capitalization of $1.02 billion, a price-to-earnings ratio of -1,208.05 and a beta of 1.79. The stock's 50-day simple moving average is $28.59 and its 200 day simple moving average is $27.72. The company has a current ratio of 1.88, a quick ratio of 1.33 and a debt-to-equity ratio of 0.71.

Artivion (NYSE:AORT - Get Free Report) last announced its quarterly earnings results on Monday, February 24th. The company reported ($0.39) earnings per share for the quarter, missing analysts' consensus estimates of $0.12 by ($0.51). Artivion had a negative net margin of 0.22% and a positive return on equity of 5.15%. The company had revenue of $97.31 million for the quarter, compared to analyst estimates of $100.82 million. On average, equities analysts anticipate that Artivion, Inc. will post 0.37 EPS for the current year.

Insider Buying and Selling at Artivion

In other Artivion news, CEO James P. Mackin sold 42,156 shares of Artivion stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $27.31, for a total transaction of $1,151,280.36. Following the completion of the sale, the chief executive officer now directly owns 663,882 shares in the company, valued at $18,130,617.42. This trade represents a 5.97 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Jean F. Holloway sold 18,020 shares of Artivion stock in a transaction dated Tuesday, March 11th. The shares were sold at an average price of $23.61, for a total transaction of $425,452.20. Following the sale, the senior vice president now owns 197,184 shares of the company's stock, valued at approximately $4,655,514.24. This represents a 8.37 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 90,799 shares of company stock worth $2,356,223 over the last three months. Insiders own 8.10% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on AORT shares. Stifel Nicolaus decreased their price target on shares of Artivion from $33.00 to $30.00 and set a "buy" rating on the stock in a research note on Tuesday, February 25th. JMP Securities reissued a "market outperform" rating and issued a $33.00 price target on shares of Artivion in a research note on Tuesday, December 10th. Finally, Needham & Company LLC cut their price objective on shares of Artivion from $34.00 to $32.00 and set a "buy" rating for the company in a research report on Tuesday, February 25th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Artivion has a consensus rating of "Buy" and a consensus target price of $31.40.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.